A randomized controlled trial for low-dose continuous Infusion of human atrial natriuretic peptide for high risk patients undergoing cardiac surgery

A randomized controlled trial for low-dose continuous Infusion of human atrial natriuretic peptide for high risk patients undergoing cardiac surgery - NU-HIT trial for High risk patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004537

Enrollment

350

Registered

2010-11-10

Start date

1997-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

myocardial infarction, angina

Interventions

Perioperative administration of hANP (0.02ganma) Perioperative non-administration of hANP

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: EuroScore>6 point On pump CABG Patients from whom informed consent was obtained

Exclusion criteria

Exclusion criteria: OPCAB Combined surgery

Design outcomes

Primary

Measure	Time frame
major adverse cardiovascular and cerebrovascular events (MACCE)	—

Secondary

Measure	Time frame
1) postoperative death (early, late) 2) MACCE + hemodialysis (HD) 3) serum creatinine (sCr) and brain natriuretic peptide (BNP) levels at 1 week and 1 year postoperatively.	—

Countries

Japan

Contacts

Public ContactAkira Sezai

Nihon University school of medicine Department of Cardiovascular Surgery

asezai.med@gmail.com03-3972-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026